Ishita Drugs & Industries Ltd
Fundamental Score
Ishita Drugs & Industries Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ISHITADR across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Attractive Valuation (P/E: 22.26 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Conservative Debt Levels (D/E: 0.18)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (17.25x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
8 factors identified
Below-Average Return on Equity (8.40%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.91%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Profit Decline Concern (-26.32%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-6.12%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Limited Growth History (0.23% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Negative Free Cash Flow (₹-2.37 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Ishita Drugs & Industries Ltd
About ISHITADR
Business Overview
Ishita Drugs and Industries Limited manufactures and sells active pharma ingredients (APIs), fine chemicals, drug intermediates, and excipients in India and internationally. The company offers APIs, such as sulfa drugs/sulfonamides, vitamins, fluoro quinolones, antibiotics, anthelmintics, iodides and citrates, food additives/excipients, and others. It also provides contract manufacturing services for various drug intermediates, fine chemicals, or specialty chemicals. Ishita Drugs and Industries Limited was incorporated in 1992 and is based in Ahmedabad, India.
Company Details
Key Leadership
ISHITADR Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Ishita Drugs & Industries Ltd (ISHITADR)?
As of 29 Jan 2026, 10:37 am IST, Ishita Drugs & Industries Ltd (ISHITADR) is currently trading at ₹68.38. The stock has a market capitalization of ₹21.59 (Cr).
Is ISHITADR share price Overvalued or Undervalued?
ISHITADR is currently trading at a P/E ratio of 22.26x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Ishita Drugs & Industries Ltd share price?
Key factors influencing ISHITADR's price include its quarterly earnings growth (Sales Growth: -6.12%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Ishita Drugs & Industries Ltd a good stock for long-term investment?
Ishita Drugs & Industries Ltd shows a 5-year Profit Growth of 9.61% and an ROE of 8.40%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.18 before investing.
How does Ishita Drugs & Industries Ltd compare with its industry peers?
Ishita Drugs & Industries Ltd competes with major peers in the Pharmaceuticals. Investors should compare ISHITADR's P/E of 22.26x and ROE of 8.40% against the industry averages to determine its competitive standing.
What is the P/E ratio of ISHITADR and what does it mean?
ISHITADR has a P/E ratio of 22.26x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹22 for every ₹1 of annual earnings.
How is ISHITADR performing according to Bull Run's analysis?
ISHITADR has a Bull Run fundamental score of 29.3/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does ISHITADR belong to?
ISHITADR operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Ishita Drugs & Industries Ltd.
What is Return on Equity (ROE) and why is it important for ISHITADR?
ISHITADR has an ROE of 8.40%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Ishita Drugs & Industries Ltd generates profits from shareholders' equity.
How is ISHITADR's debt-to-equity ratio and what does it indicate?
ISHITADR has a debt-to-equity ratio of 0.18, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is ISHITADR's dividend yield and is it a good dividend stock?
ISHITADR offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has ISHITADR grown over the past 5 years?
ISHITADR has achieved 5-year growth rates of: Sales Growth 0.23%, Profit Growth 9.61%, and EPS Growth 9.61%.
What is the promoter holding in ISHITADR and why does it matter?
Promoters hold 49.96% of ISHITADR shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is ISHITADR's market capitalization category?
ISHITADR has a market capitalization of ₹22 crores, placing it in the Small-cap category.
How volatile is ISHITADR stock?
ISHITADR has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for ISHITADR?
ISHITADR has a 52-week high of ₹N/A and low of ₹N/A.
What is ISHITADR's operating profit margin trend?
ISHITADR has a 5-year average Operating Profit Margin (OPM) of 6.63%, indicating the company's operational efficiency.
How is ISHITADR's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -6.12% and YoY Profit Growth of -26.32%.
What is the institutional holding pattern in ISHITADR?
ISHITADR has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.